AC Immune (ACIU) Receivables - Net (2015 - 2024)
AC Immune (ACIU) reported Receivables - Net of $28.4 million for Q3 2024, down 99.83% on a QoQ basis from $16.7 billion in Q4 2023.
AC Immune (ACIU) has 5 years of Receivables - Net data on file, last reported at $28.4 million in Q3 2024.
- Quarterly Receivables - Net changed N/A year-over-year to $28.4 million in Q3 2024, while the trailing twelve-month figure through Sep 2024 was $28.4 million (changed N/A YoY) and the FY2023 annual result came in at $16.7 billion, changed N/A from the prior year.
- Receivables - Net retreated to $28.4 million in Q3 2024 per ACIU's latest filing, from $16.7 billion in the prior quarter.
- Across five years, Receivables - Net topped out at $16.7 billion in Q4 2023 and bottomed at $28.4 million in Q3 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | AC Immune | 325.88 Mn | 211.53 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 28.39 Mn |
| Sep 30, 2024 | 28.39 Mn |
| Dec 31, 2023 | 16.68 Bn |
| Dec 31, 2023 | 16.68 Bn |
| Sep 30, 2019 | 101,495.14 |
| Sep 30, 2019 | 101,495.14 |
| Jun 30, 2019 | 97.74 |
| Jun 30, 2019 | 97.74 |
| Mar 31, 2019 | 201,816.57 |
| Mar 31, 2019 | 201,816.57 |
| Dec 31, 2018 | 199,962.12 |
| Dec 31, 2018 | 199,962.12 |
| Dec 31, 2015 | 104,084.80 |
| Dec 31, 2015 | 104,084.80 |